High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy
出版年份 2021 全文链接
标题
High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy
作者
关键词
-
出版物
Cancers
Volume 13, Issue 11, Pages 2548
出版商
MDPI AG
发表日期
2021-05-24
DOI
10.3390/cancers13112548
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Antibody-Drug Conjugates in Urothelial Carcinomas
- (2020) Michal Sarfaty et al. Current Oncology Reports
- European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
- (2020) J. Alfred Witjes et al. EUROPEAN UROLOGY
- Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma
- (2020) Eisuke Tomiyama et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients
- (2020) Tibor Szarvas et al. Diagnostics
- Soluble Ligand of the Immune Checkpoint Receptor (sPD-L1) in Blood Serum of Patients with Renal Cell Carcinoma
- (2019) N. E. Kushlinskii et al. BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE
- Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
- (2019) Tetsuro Tominaga et al. PLoS One
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
- (2019) Thomas Powles et al. NATURE MEDICINE
- A húgyhólyag urothelialis daganatainak molekuláris alcsoportbeosztása és annak klinikai vonatkozásai
- (2019) Tibor Szarvas et al. ORVOSI HETILAP
- Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab
- (2018) Adrien Costantini et al. OncoImmunology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression
- (2018) Tsunehiko Shigemori et al. ANNALS OF SURGICAL ONCOLOGY
- FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
- (2018) Daniel L. Suzman et al. ONCOLOGIST
- Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage
- (2017) Mayuko Hira-Miyazawa et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy
- (2017) Yang‐Min Ning et al. ONCOLOGIST
- sPD-L1 Expression is Associated with Immunosuppression and Infectious Complications in Patients with Acute Pancreatitis
- (2017) Y. Chen et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy
- (2017) Renate Pichler et al. Oncotarget
- Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
- (2017) Xinxin Zhu et al. Oncotarget
- ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy
- (2016) Floris H. Groenendijk et al. EUROPEAN UROLOGY
- PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
- (2016) Melanie Ruf et al. INTERNATIONAL JOURNAL OF CANCER
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma
- (2016) Takehiko Fukuda et al. Cancer Medicine
- A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage
- (2015) Colette Dezutter-Dambuyant et al. OncoImmunology
- High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
- (2014) D Rossille et al. LEUKEMIA
- Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer
- (2010) Tibor Szarvas et al. BJU INTERNATIONAL
- Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer
- (2010) Tibor Szarvas et al. CANCER SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started